Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2007

View Archived Issues

Long-term antiarthritic efficacy of a pseudotyped AAV2/1-TNFR:Fc vector shown in rats

CardioMetabolics updates progress in development of DCA

Michael J. Fox Foundation funds industry development efforts in Parkinson's

Preclinical profile of GW-590735 described at GSK

Ajinomoto licenses antidiabetic agent to Boehringer Ingelheim

Valeant develops intranasal diazepam for seizure emergencies

Galiximab studied with rituximab for follicular NHL

Pyramax begins pivotal program in malaria

Januvia recommended for approval in E.U.

Copegus approved for use in combination with Pegasys in Japan

Lilly completes acquisition of ICOS

Pentacel recommended for approval

Atiprimod considered for HCC treatment

CYT006-AngQb shows reduction in daytime blood pressure in phase IIa study

Remicade approved in Japan for Behcet's disease with refractory uveoretinitis

Japanese approval for oral Fludara

Tarceva approved in Europe for metastatic pancreatic cancer

New approval for Funguard in Japan

Prograf approved in Japan for lupus nephritis

Japanese approval for Modiodal in narcolepsy

Somavert approved for acromegaly in Japan

T-0047 clinical testing resumes

Promising preclinical results with Novartis Smac mimetic for the treatment of multiple myeloma

Recent Allergan and Florida Atlantic University patents divulge novel analgesic agents

Novel immunomodulatory agents imparted in recent Astellas patent

European CHMP hands down positive opinions for Xyrem and Prevenar

Novel antidiabetic agents disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...